Results 111 to 120 of about 6,146 (182)

Comparative study on the cardioprotective effects against ischemia/reperfusion injury of the selective SGLT2 inhibitors, empagliflozin, dapagliflozin and ertugliflozin in non-diabetic mice [PDF]

, 2021
Nikolaos Mylonas, Panagiota Nikolaou, Panagiotis Efentakis, George Dimitriadis, Efstathios K. Iliodromitis, Ioanna Andreadou   +5 more
openalex   +1 more source

EMPAGLIFLOZIN RENAL SAFETY IN NORMOGLYCEMIC RATS WITH HEART FAILURE

, 2018
С. В. Оковитый, Olga Beresneva, Marina Parastaeva, Г. Т. Иванова, D. Yu. Ivkin, A. S. Ivkina, В. Г. Сиповский, M. I. Zaraiyskii`, А. А. Карпов, А. Г. Кучер, Evdokia Bogdanova, E. B. Sipovskaya, Alexander N. Kulikov, I. G. Kayukov   +13 more
openalex   +1 more source

Effects of empagliflozin on exercise tolerance and left ventricular diastolic function in patients with heart failure with preserved ejection fraction and type 2 diabetes: a prospective single-center study

, 2021
А. Г. Овчинников, Borisov Aa, Kristina Zherebchikova, O Yu Ryabtseva, A. D. Gvozdeva, В. П. Масенко, Ф. Т. Агеев, S. А. Boytsov   +7 more
openalex   +1 more source

Synergistic associations of metformin and GLP‐1 receptor agonist use with adiposity‐related cancer incidence in people living with type 2 diabetes

Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 946-959, February 2026.
Abstract Background Metformin and glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) may reduce the risk of adiposity‐related cancers in patients with type 2 diabetes (T2D). The potential synergistic effects of these treatments on cancer incidence remain unclear, considering their distinct biological mechanisms and their associated effects on body ...
Alex E. Henney, Megan Heague, David R. Riley, Theresa J. Hydes, Matthew Anson, Uazman Alam, Daniel J. Cuthbertson   +6 more
wiley   +1 more source

One‐year usage patterns of SGLT‐2 inhibitors and GLP‐1 receptor agonists in individuals with type 2 diabetes in a real‐world population

Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 972-981, February 2026.
Abstract Aims Real‐world studies of sodium‐glucose co‐transporter‐2 inhibitors (SGLT2i) and glucagon‐like peptide‐1 receptor agonists (GLP‐1RA) typically assess adherence and discontinuation as separate outcomes. We applied a novel approach that integrates these measures to categorize patterns of drug usage.
Louise A. Donnelly, Katyayeni Singh, Rory J. McCrimmon, Ewan R. Pearson   +3 more
wiley   +1 more source

Retinopathy Outcomes With Empagliflozin Versus Placebo in the EMPA-REG OUTCOME Trial

, 2019
Silvio E. Inzucchi, Christoph Wanner, Uwe Hehnke, Isabella Zwiener, Stefan Kaspers, Douglas Clark, Jyothis T. George, Bernard Zinman   +7 more
openalex   +2 more sources

Ethnic differences in the comparative effectiveness of second‐line type 2 diabetes medications in preventing cardiovascular disease

Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 1013-1023, February 2026.
Abstract Aim To investigate ethnic differences in the comparative effectiveness of sulfonylureas (SU), dipeptidyl peptidase‐4 inhibitors (DPP4i) and sodium‐glucose cotransporter‐2 inhibitors (SGLT2i) on cardiovascular outcomes. Materials and Methods We identified adults with type 2 diabetes in UK electronic health records initiating SU, DPP4i or SGLT2i
Mia Harley, Christopher T. Rentsch, Elizabeth Williamson, Anoop S. V. Shah, Patrick Bidulka, Charlotte Warren‐Gash, Marleen Bokern, Rohini Mathur   +7 more
wiley   +1 more source

Combination of the sodium-glucose cotransporter-2 inhibitor empagliflozin with orlistat or sibutramine further improves the body-weight reduction and glucose homeostasis of obese rats fed a cafeteria diet

Diabetes, Metabolic Syndrome and Obesity, 2014
Steven P Vickers,1 Sharon C Cheetham,1 Katie R Headland,1 Keith Dickinson,1 Rolf Grempler,2 Eric Mayoux,2 Michael Mark,2 Thomas Klein2 1RenaSci, BioCity Nottingham, Nottingham, UK; 2Boehringer Ingelheim Pharma, Biberach an der Riss, Germany Abstract ...
Vickers SP, Cheetham SC, Headl, KR, Dickinson K, Grempler R, Mayoux E, Mark M, Klein T   +8 more
doaj  

Effects of SGLT2 inhibitors across the spectrum of albuminuria in cardiovascular–kidney–metabolic conditions: A pooled analysis of randomised trials

Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 1105-1115, February 2026.
Abstract Background Albuminuria is associated with an increased risk of cardiovascular and kidney events. Sodium glucose co‐transporter 2 inhibitors (SGLT2i) reduce albuminuria and improve kidney outcomes in patients with albuminuric chronic kidney disease (CKD).
João Pedro Ferreira, Pedro Marques, Stefan D. Anker, Javed Butler, Gerasimos Filippatos, Abhinav Sharma, Francisco Vasques‐Nóvoa, Luís Mendonça, João Sérgio Neves, Milton Packer, Faiez Zannad   +10 more
wiley   +1 more source

Empagliflozin attenuates ventricular fibrillation postmyocardial infarction associated with reduced transforming growth factor-1/Smad3 signaling and miR-181a expression

Journal of International Medical Research
Objective To determine whether empagliflozin reduces ventricular fibrillation and myocardial fibrosis after myocardial infarction via the transforming growth factor-β1/Smad3/miR-181a pathway.
Jingsong Shen, Min Huang, Zixu Ye, Yuling Jing, Ziyang Yuan, Zeming Xiang, Miao Ding, Tao Li, Qiang Ye   +8 more
doaj   +1 more source